Search: onr:"swepub:oai:lup.lub.lu.se:03fe2c0f-ad77-446e-818d-8e71edebb945" >
NovoSeven in warfar...
NovoSeven in warfarin-treated patients
-
- Berntorp, Erik (author)
- Lund University,Lunds universitet,Klinisk koagulationsmedicin, Malmö,Forskargrupper vid Lunds universitet,Clinical Coagulation, Malmö,Lund University Research Groups
-
Stigendal, L (author)
-
- Lethagen, Stefan (author)
- Lund University,Lunds universitet,Institutionen för kliniska vetenskaper, Malmö,Medicinska fakulteten,Department of Clinical Sciences, Malmö,Faculty of Medicine
-
show more...
-
Olofsson, L (author)
-
Hedner, U (author)
-
show less...
-
(creator_code:org_t)
- 2000
- 2000
- English.
-
In: Blood Coagulation and Fibrinolysis. - 1473-5733. ; 11:Suppl 1, s. 113-115
- Related links:
-
https://lup.lub.lu.s...
Abstract
Subject headings
Close
- Haemorrhages represent a major complication of treatment with vitamin K antagonists. In cases of severe bleeding, a prompt effect on the increased International Normalized Ratio value is vital to achieve haemostasis. As conventional treatment, that is plasma or plasma-derived concentrates, carries the risk of blood-borne virus transmission, new treatments are needed. An open, multicentre pilot trial is currently under way to determine the effect of recombinant activated factor VII (rFVIIa; NovoSeven) administered to patients experiencing a bleeding episode after receiving vitamin K antagonists. When rFVIIa was given to a patient with a warfarin-induced nosebleed, it had an immediate haemostatic effect and the International Normalized Ratio value virtually normalized.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database